JP2013521314A - 癌の処置のためのチゲサイクリンの使用 - Google Patents
癌の処置のためのチゲサイクリンの使用 Download PDFInfo
- Publication number
- JP2013521314A JP2013521314A JP2012556354A JP2012556354A JP2013521314A JP 2013521314 A JP2013521314 A JP 2013521314A JP 2012556354 A JP2012556354 A JP 2012556354A JP 2012556354 A JP2012556354 A JP 2012556354A JP 2013521314 A JP2013521314 A JP 2013521314A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cells
- mitochondrial
- tigecycline
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31241010P | 2010-03-10 | 2010-03-10 | |
| US61/312,410 | 2010-03-10 | ||
| PCT/CA2011/000258 WO2011109899A1 (en) | 2010-03-10 | 2011-03-10 | Use of tigecycline for treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013521314A true JP2013521314A (ja) | 2013-06-10 |
| JP2013521314A5 JP2013521314A5 (enExample) | 2014-04-24 |
Family
ID=44562767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012556354A Withdrawn JP2013521314A (ja) | 2010-03-10 | 2011-03-10 | 癌の処置のためのチゲサイクリンの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20120329761A1 (enExample) |
| EP (1) | EP2544692A4 (enExample) |
| JP (1) | JP2013521314A (enExample) |
| CN (1) | CN102821769A (enExample) |
| CA (1) | CA2790240A1 (enExample) |
| WO (1) | WO2011109899A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2842228A1 (en) * | 2011-07-15 | 2013-01-24 | University Health Network | Combination treatment for cancer |
| WO2014029016A1 (en) * | 2012-08-24 | 2014-02-27 | University Health Network | Compositions comprising a glycylcycline and a tyrosine kinase inhibitor for treating cancer |
| CN108329312B (zh) | 2012-08-31 | 2021-12-31 | 四相制药公司 | 四环素化合物 |
| EP3327144B1 (en) | 2013-02-25 | 2020-03-25 | Novartis AG | Novel androgen receptor mutation |
| CN103142624A (zh) * | 2013-03-01 | 2013-06-12 | 西南大学 | 抗生素替加环素在制备抗癌药物中的应用 |
| WO2014138338A1 (en) * | 2013-03-06 | 2014-09-12 | The General Hospital Corporation | Combinatorial compositions and methods for treatment of melanoma |
| CN110167560B (zh) * | 2016-08-30 | 2023-08-18 | 四相制药公司 | 四环素化合物和治疗方法 |
| HUE066360T2 (hu) | 2016-10-19 | 2024-07-28 | Tetraphase Pharmaceuticals Inc | Eravaciklin kristályformái |
| PH12019502594A1 (en) | 2017-05-19 | 2020-10-26 | Lunella Biotech Inc | Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| CN109331026A (zh) * | 2018-04-21 | 2019-02-15 | 温州医科大学附属第医院 | 替加环素在制备抗多发性骨髓瘤药物中的应用 |
| CA3102264A1 (en) * | 2018-06-19 | 2019-12-26 | Lunella Biotech, Inc. | "energetic" cancer stem cells (e-cscs): a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837696A (en) * | 1997-01-15 | 1998-11-17 | The Research Foundation Of State University Of New York | Method of inhibiting cancer growth |
| WO2001035096A2 (en) * | 1999-11-10 | 2001-05-17 | Mitokor | Diseases associated with altered mitochondrial function |
| WO2002038759A2 (en) * | 2000-11-10 | 2002-05-16 | Mitotech Ab | Method for inducing apoptiosis |
| JP2005505588A (ja) * | 2001-10-05 | 2005-02-24 | テトラジェネックス ファーマスーティカルズ インク | テトラサイクリン誘導体、及びそれを使用する方法 |
| WO2004064728A2 (en) * | 2003-01-16 | 2004-08-05 | Paratek Pharmaceuticals, Inc. | Use of specific tetracycline compounds in therapy |
| US20050148553A1 (en) * | 2003-09-05 | 2005-07-07 | Testa Raymond T. | Use of tigecycline, alone, or in combination with rifampin to treat osteomyelitis and/or septic arthritis |
| AR057032A1 (es) * | 2005-05-27 | 2007-11-14 | Wyeth Corp | Tigeciclina y metodos de preparacion |
-
2011
- 2011-03-10 EP EP11752777.0A patent/EP2544692A4/en not_active Withdrawn
- 2011-03-10 CA CA2790240A patent/CA2790240A1/en not_active Abandoned
- 2011-03-10 CN CN201180013184XA patent/CN102821769A/zh active Pending
- 2011-03-10 JP JP2012556354A patent/JP2013521314A/ja not_active Withdrawn
- 2011-03-10 US US13/582,842 patent/US20120329761A1/en not_active Abandoned
- 2011-03-10 WO PCT/CA2011/000258 patent/WO2011109899A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN102821769A (zh) | 2012-12-12 |
| US20120329761A1 (en) | 2012-12-27 |
| WO2011109899A1 (en) | 2011-09-15 |
| CA2790240A1 (en) | 2011-09-15 |
| EP2544692A1 (en) | 2013-01-16 |
| EP2544692A4 (en) | 2013-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013521314A (ja) | 癌の処置のためのチゲサイクリンの使用 | |
| AU2013342267B2 (en) | Small molecule inhibitors of MALT1 | |
| JP5688288B2 (ja) | がんの処置のための相乗的な医薬の組合せ | |
| JP6132833B2 (ja) | 抗癌療法としての正常細胞および腫瘍細胞の小分子trail遺伝子誘導 | |
| US9771625B2 (en) | Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer | |
| US20210186993A1 (en) | Combination therapies targeting mitochondria for cancer therapy | |
| TWI759316B (zh) | Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物 | |
| JP2014514326A5 (enExample) | ||
| EP2880014A1 (en) | Compounds for the treatment of mtor pathway related diseases | |
| CN102791260A (zh) | 低氧诱导因子抑制剂的用途 | |
| EP3062790A1 (en) | Pharmaceutical combinations for the treatment of cancer | |
| JP2009543874A (ja) | チアゾリジノン誘導体 | |
| US20140221301A1 (en) | Combination treatment for cancer | |
| WO2014029016A1 (en) | Compositions comprising a glycylcycline and a tyrosine kinase inhibitor for treating cancer | |
| US11583509B2 (en) | Compound for treating cancer and diabetes | |
| US20220016118A1 (en) | Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof | |
| EP3405194B1 (en) | A temporary inhibitor of p53 in combination with an anticancer agent for use in the preventing or reducing cancer relapse | |
| US20230201168A1 (en) | New therapy for the treatment of tumors | |
| JP2024506847A (ja) | がんを処置および改善するための方法 | |
| WO2019168177A1 (ja) | 癌の予防または治療剤 | |
| WO2024023279A1 (en) | Cancer combination therapy including a bcl-2 inhibitor | |
| Kokkinis et al. | Liposomal Encapsulated Curcumin Attenuates Lung Cancer Proliferation, Migration and Apoptosis | |
| NZ622752A (en) | Romidepsin and 5 - azacitidine for use in treating lymphoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140310 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140310 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20141008 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20141008 |